Pembrolizumab plus chemo before surgery for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving pembrolizumab (an immune therapy) plus chemotherapy before surgery can improve outcomes for people with locally advanced, operable esophageal squamous cell carcinoma. It may help shrink the tumor and improve the chance of successful surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older, and have confirmed esophageal squamous cell cancer that can be removed with surgery.
- Your cancer is stage cT2 to cT4a, with no distant spread (M0), and you have not had cancer treatment before.
- A scan must show measurable tumor spots, and you must be able to provide recent or existing tumor tissue samples.
- Your overall health score (ECOG) is 0 or 1, meaning you are fully active or limited in activity but not bedridden.
- Your organs must be strong enough for treatment (blood/organ tests done shortly before starting).
- You must sign written consent and meet pregnancy/contraception rules during treatment and for several months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called Adebrelimab combined with chemotherapy before surgery for esophageal cancer. It aims to shrink the tumor and make it easier to remove completely.
This Phase 3 study compares two treatment plans before surgery for locally advanced esophageal squamous cell carcinoma. It tests whether adding pembrolizumab (an immune therapy) to chemotherapy improves outcomes compared with standard chemoradiation.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
This trial tests a combination of an immunotherapy drug (serplulimab) and two chemotherapy drugs (nab-paclitaxel and cisplatin) given before surgery for esophageal cancer that can be removed. The goal is to see if this treatment helps shrink the tumor and improve outcomes for patients with stage IB to III esophageal squamous cell carcinoma.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial is testing different treatment combinations before surgery for people with locally advanced esophageal squamous cell carcinoma. The goal is to find which approach works best based on specific biomarkers like PD-L1 levels.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.